ES2288997T3 - Procedimiento para producir cristales de nateglinida de tipo b. - Google Patents

Procedimiento para producir cristales de nateglinida de tipo b. Download PDF

Info

Publication number: ES2288997T3
Authority: ES; Spain
Prior art keywords: crystals; nateglinide; type; wet; drying
Prior art date: 2000-10-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES01976819T

Other languages

English (en)

Spanish (es)

Inventor

Michito c/o Tokai Plant SUMIKAWA

Makoto c/o Tokai Plant MARUO

Kazuo c/o Tokai Plant MIYAZAKI

Shigehiro c/o Tokai Plant NISHINA

Yukiko c/o Tokai Plant MATSUZAWA

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ajinomoto Co Inc

Original Assignee

Ajinomoto Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-24

Filing date

2001-10-23

Publication date

2008-02-01

2001-10-23 Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc

2008-02-01 Application granted granted Critical

2008-02-01 Publication of ES2288997T3 publication Critical patent/ES2288997T3/es

2021-10-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000013078 crystal Substances 0.000 title claims abstract description 96
238000000034 method Methods 0.000 title claims description 19
OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 title description 2
229960000698 nateglinide Drugs 0.000 claims abstract description 39
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims abstract description 37
238000001035 drying Methods 0.000 claims abstract description 11
238000006243 chemical reaction Methods 0.000 claims abstract description 10
239000002904 solvent Substances 0.000 claims abstract description 10
238000010438 heat treatment Methods 0.000 claims abstract description 5
239000012453 solvate Substances 0.000 claims description 5
238000001816 cooling Methods 0.000 claims description 3
-1 nateglinide hydrates Chemical class 0.000 claims description 3
150000004677 hydrates Chemical class 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 abstract description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
238000002425 crystallisation Methods 0.000 description 6
230000008025 crystallization Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000035800 maturation Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
230000000052 comparative effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Crystallography & Structural Chemistry (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES01976819T 2000-10-24 2001-10-23 Procedimiento para producir cristales de nateglinida de tipo b. Expired - Lifetime ES2288997T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000324375		2000-10-24
JP2000-324375		2000-10-24

Publications (1)

Publication Number	Publication Date
ES2288997T3 true ES2288997T3 (es)	2008-02-01

Family

ID=18801920

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES01976819T Expired - Lifetime ES2288997T3 (es)	2000-10-24	2001-10-23	Procedimiento para producir cristales de nateglinida de tipo b.

Country Status (18)

Country	Link
US (2)	US20030229249A1 (2)
EP (1)	EP1334964B1 (2)
JP (1)	JP4225057B2 (2)
KR (1)	KR100810930B1 (2)
CN (1)	CN100422143C (2)
AT (1)	ATE370115T1 (2)
AU (1)	AU2001296001A1 (2)
BR (1)	BR0114846A (2)
CA (1)	CA2426745C (2)
CY (1)	CY1106839T1 (2)
DE (1)	DE60130014T2 (2)
DK (1)	DK1334964T3 (2)
ES (1)	ES2288997T3 (2)
MX (1)	MXPA03003575A (2)
PT (1)	PT1334964E (2)
RU (1)	RU2275354C2 (2)
TW (1)	TWI293290B (2)
WO (1)	WO2002034713A1 (2)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20070104953A (ko) *	2000-03-17	2007-10-29	아지노모토 가부시키가이샤	신경 장애용 약제
PT1334962E (pt) *	2000-10-18	2007-10-09	Ajinomoto Kk	''processo de preparação de acilfenilalaninas''
CA2425538C (en) *	2000-10-18	2010-10-12	Ajinomoto Co., Inc.	Methods for producing nateglinide crystals
RU2271805C2 (ru) *	2000-10-24	2006-03-20	Адзиномото Ко., Инк.	Препарат, содержащий натеглинид
ATE429217T1 (de) *	2000-10-24	2009-05-15	Ajinomoto Kk	Nateglinid enthaltende hydrophile arzneimittelpräparate
US7411089B2 (en)	2002-04-15	2008-08-12	Ajinomoto Co., Inc.	Nateglinide crystals
EP2264004A1 (en) *	2002-04-15	2010-12-22	Ajinomoto Co., Inc.	New nateglinide crystals
US6861553B2 (en)	2002-07-03	2005-03-01	Teva Pharmaceuticals Industries Ltd.	Process for preparing nateglinide and intermediates thereof
US7534913B2 (en)	2002-07-18	2009-05-19	Teva Pharmaceutica Industries Ltd.	Crystalline form of nateglinide
EP1467964A1 (en) *	2002-07-18	2004-10-20	Teva Pharmaceutical Industries Limited	Polymorphic forms of nateglinide
US7420084B2 (en)	2002-07-18	2008-09-02	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
US7148376B2 (en)	2002-07-18	2006-12-12	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
US7358390B2 (en)	2002-07-18	2008-04-15	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
DE60310734T2 (de) *	2003-11-26	2007-10-11	A.M.S.A. Anonima Matèrie Sintètiche e Affini S.p.A.	Verfahren zur Herstellung von Nateglinid in der B-Form
KR20070009726A (ko) *	2004-05-07	2007-01-18	테바 파마슈티컬 인더스트리즈 리미티드	나테글리나이드의 다형태
US20070231393A1 (en) *	2004-05-19	2007-10-04	University Of South Carolina	System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles
WO2005113485A2 (en) *	2004-05-20	2005-12-01	Dr. Reddy's Laboratories Ltd.	Stable nateglinide form b compositions
US7425648B2 (en)	2005-01-03	2008-09-16	A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A.	Process for the preparation of nateglinide, preferably in B-form
EP1891971A4 (en) *	2005-01-31	2010-02-03	Ajinomoto Kk	MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
WO2007135533A1 (en) *	2006-05-23	2007-11-29	Aurobindo Pharma Limited	Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) *	2006-12-26	2008-06-13	씨제이제일제당 (주)	나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
AU2011266820A1 (en)	2010-06-14	2013-01-24	Cipla Limited	A process for the preparation of nateglinide
US9303038B2 (en)	2011-09-06	2016-04-05	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167985A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of depression
WO2013168021A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167991A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en)	2012-05-08	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en)	2012-05-08	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of parkinson's disease
WO2013167987A1 (en) *	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of diabetes
WO2013168014A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168004A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of fibromyalgia pain
WO2013168012A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
WO2013168033A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neurologic diseases
WO2013167997A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
US9394288B2 (en)	2012-05-10	2016-07-19	Cellix Bio Private Limited	Compositions and methods for the treatment of asthma and allergy
WO2013168000A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of severe pain
WO2013167999A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en)	2012-05-10	2016-03-01	Cellix Bio Private Limited	Compositions and methods for the treatment of chronic pain
WO2013168005A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9233161B2 (en)	2012-05-10	2016-01-12	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological conditions
US9403857B2 (en)	2012-05-10	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9498461B2 (en)	2012-05-23	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
AU2013264820A1 (en)	2012-05-23	2014-11-27	Cellixbio Private Limited	Compositions and methods for treatment of mucositis
US9492409B2 (en)	2012-05-23	2016-11-15	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
WO2013175344A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en)	2012-05-23	2016-01-05	Cellex Bio Private Limited	Compositions and methods for the treatment of respiratory disorders
EP2852569B1 (en)	2012-05-23	2020-10-14	Cellixbio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en)	2012-08-03	2014-02-06	Mahesh Kandula	Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh)	2012-09-08	2015-02-18	塞利克斯比奥私人有限公司	用于治疗炎症和脂质异常的组合物和方法
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en)	2013-06-04	2018-09-05	Cellixbio Private Limited	Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
EP3240779B1 (en)	2014-09-26	2020-10-28	Cellixbio Private Limited	Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja)	2014-09-29	2020-05-27	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en)	2014-10-27	2020-04-09	Cellix Bio Private Limited	Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
CN104402756B (zh) *	2014-11-27	2016-08-31	天方药业有限公司	一种高纯度那格列奈的制备方法
US9932294B2 (en)	2014-12-01	2018-04-03	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
CA2973178C (en)	2015-01-06	2022-11-01	Cellix Bio Private Limited	Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN109369443A (zh) *	2018-11-05	2019-02-22	扬子江药业集团江苏海慈生物药业有限公司	一种新的那格列奈h晶型的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6354321A (ja) *	1985-03-27	1988-03-08	Ajinomoto Co Inc	血糖降下剤
AU615966B2 (en) *	1987-12-04	1991-10-17	Takeda Chemical Industries Ltd.	Crystals of cephem hydrochloride
DE10199058I2 (de)	1991-07-30	2006-04-27	Alcm Co	Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5463116A (en)	1991-07-30	1995-10-31	Ajinomoto Co., Inc.	Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
AU718350B2 (en) *	1996-11-15	2000-04-13	Ajinomoto Co., Inc.	Tablet composition
US6844006B1 (en) *	1999-07-09	2005-01-18	Pennfield Oil Company	Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
CZ20022294A3 (cs) *	1999-12-28	2002-11-13	Ajinomoto Co., Inc.	Antidiabetický preparát k orálnímu uľití
KR20070104953A (ko) *	2000-03-17	2007-10-29	아지노모토 가부시키가이샤	신경 장애용 약제
CA2425538C (en) *	2000-10-18	2010-10-12	Ajinomoto Co., Inc.	Methods for producing nateglinide crystals
PT1334962E (pt) *	2000-10-18	2007-10-09	Ajinomoto Kk	''processo de preparação de acilfenilalaninas''
RU2271805C2 (ru) *	2000-10-24	2006-03-20	Адзиномото Ко., Инк.	Препарат, содержащий натеглинид
US7411089B2 (en)	2002-04-15	2008-08-12	Ajinomoto Co., Inc.	Nateglinide crystals

2001
- 2001-10-23 CA CA002426745A patent/CA2426745C/en not_active Expired - Fee Related
- 2001-10-23 PT PT01976819T patent/PT1334964E/pt unknown
- 2001-10-23 JP JP2002537707A patent/JP4225057B2/ja not_active Expired - Fee Related
- 2001-10-23 RU RU2003111948/04A patent/RU2275354C2/ru not_active IP Right Cessation
- 2001-10-23 AT AT01976819T patent/ATE370115T1/de active
- 2001-10-23 WO PCT/JP2001/009293 patent/WO2002034713A1/ja not_active Ceased
- 2001-10-23 MX MXPA03003575A patent/MXPA03003575A/es active IP Right Grant
- 2001-10-23 CN CNB018212999A patent/CN100422143C/zh not_active Expired - Fee Related
- 2001-10-23 DK DK01976819T patent/DK1334964T3/da active
- 2001-10-23 AU AU2001296001A patent/AU2001296001A1/en not_active Abandoned
- 2001-10-23 KR KR1020037005671A patent/KR100810930B1/ko not_active Expired - Fee Related
- 2001-10-23 EP EP01976819A patent/EP1334964B1/en not_active Expired - Lifetime
- 2001-10-23 ES ES01976819T patent/ES2288997T3/es not_active Expired - Lifetime
- 2001-10-23 BR BR0114846-0A patent/BR0114846A/pt not_active IP Right Cessation
- 2001-10-23 DE DE60130014T patent/DE60130014T2/de not_active Expired - Lifetime
- 2001-10-24 TW TW090126305A patent/TWI293290B/zh not_active IP Right Cessation
2003
- 2003-04-24 US US10/421,888 patent/US20030229249A1/en not_active Abandoned
2007
- 2007-06-04 US US11/757,769 patent/US7544834B2/en not_active Expired - Fee Related
- 2007-08-28 CY CY20071101136T patent/CY1106839T1/el unknown

Also Published As

Publication number	Publication date
RU2275354C2 (ru)	2006-04-27
DK1334964T3 (da)	2007-09-24
CY1106839T1 (el)	2012-05-23
EP1334964A1 (en)	2003-08-13
KR20030059212A (ko)	2003-07-07
ATE370115T1 (de)	2007-09-15
EP1334964B1 (en)	2007-08-15
PT1334964E (pt)	2007-09-20
WO2002034713A1 (en)	2002-05-02
BR0114846A (pt)	2004-02-25
MXPA03003575A (es)	2003-07-14
US20070232829A1 (en)	2007-10-04
TWI293290B (2)	2008-02-11
CA2426745C (en)	2009-09-15
JPWO2002034713A1 (ja)	2004-03-04
DE60130014D1 (de)	2007-09-27
US20030229249A1 (en)	2003-12-11
CN100422143C (zh)	2008-10-01
KR100810930B1 (ko)	2008-03-10
CA2426745A1 (en)	2003-04-23
JP4225057B2 (ja)	2009-02-18
EP1334964A4 (en)	2005-09-28
CN1483018A (zh)	2004-03-17
AU2001296001A1 (en)	2002-05-06
DE60130014T2 (de)	2008-05-08
US7544834B2 (en)	2009-06-09

Publication	Publication Date	Title
ES2288997T3 (es)	2008-02-01	Procedimiento para producir cristales de nateglinida de tipo b.
ES2965853T3 (es)	2024-04-17	Sulfonación de alcanos sin disolventes
ES2336287T5 (es)	2013-04-02	Modificaciones polimórficas de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico y procedimientos para su preparación
ES2378990T3 (es)	2012-04-19	Procedimiento para producir un compuesto imida
ES2366063T3 (es)	2011-10-14	Procedimiento para la preparación de sucralosa por cloración de azúcar con trifosgeno (btc).
ES2316755T3 (es)	2009-04-16	Preparaciones de una acetamida de sulfinilo.
Steiger	1944	Benzoylation of amino acids
KR20130108975A (ko)	2013-10-07	리네졸리드의 제조 방법
ES2879294T3 (es)	2021-11-22	Formas polimórficas de Belinostat y procesos para la preparación de las mismas
ES2386792T3 (es)	2012-08-30	Preparación de iodixanol
ES2777200T3 (es)	2020-08-04	Procedimiento para la preparación de 3-aminopiperidina enriquecida enantioméricamente
BRPI0720465B1 (pt)	2018-11-27	processo para produção de composto de precursor para composto orgânico marcado com halogênio radioativo
BRPI0111255B1 (pt)	2015-08-18	Processo para a preparação de uma sulfonamida
BRPI0615767A2 (pt)	2011-05-24	processo melhorado para a preparação de compostos de aminodiol protegido por oxazolidina úteis como intermediários para florfenicol
ES2301662T3 (es)	2008-07-01	Polimorfo de clorhidrato de fexofenadina.
JP2004518687A (ja)	2004-06-24	アルコールをカルバモイル化する方法
ES2553574T3 (es)	2015-12-10	Polimorfos de un principio activo farmacéutico
ES2279921T3 (es)	2007-09-01	Procedimiento para la preparacion de nateglinida preferentemente en forma b.
Newcombe	1955	Mesyl derivatives of hydrazine
ES2369113T3 (es)	2011-11-25	Procedimiento mejorado para producir moxonidina.
CN106496058B (zh)	2018-11-16	非离子型造影剂碘佛醇中间体的制备方法
BR112021005584A2 (pt)	2021-06-29	processo para preparar o composto 2,2-difluoro-n-((1r,2s-3-fluoro-1-hidróxi-1-(4-(6-(s-metilsulfonimidoil)piridin-3-il)fenil)propan-2-il)acetamida
ES2338871T3 (es)	2010-05-13	Proceso para la preparacion de cristales de zonisamida sin 1,2-dicloroetano y cristales de zonisamida muy puros.
ES2379910T3 (es)	2012-05-04	Cristalización de yodixanol utilizando ultrasonido
ES2248563T3 (es)	2006-03-16	Procedimiento de produccion de n-alquil-2-benzotiazolil-sulfenimidas, y su procedimiento de purificacion.